BioDlink International Co 1875.HK · HKD

Its shares trade on HKEX under the ticker 1875.HK. It has been listed since 8 November 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥870.9m and a net loss of CN¥116.9m. At that date it held total assets of CN¥1.47bn and shareholders' equity of CN¥729.3m.

TOT BIOPHARM International Co. Ltd. clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2019-11-08. The firm has a portfolio of oncology drug candidates, which include monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), oncolytic virus products and specialty oncology drugs such as liposome drugs.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Shan FuNon-Executive Chairman of the Board
• Dr. Jun LiuChief Executive Officer, Chief Scientific Officer, Executive Director, since 2018CN¥3.4m
• Ms. Chun- Ying Yeh- HuangNon-Executive Vice Chairman of the Board, since 2016CN¥3.2m
• Dr. Qing DuanSenior Director of the New Drug Development
• Ms. Shan FengSenior Director of the Regulatory Affairs Department
• Mr. Chih- Yuan WuSenior Director of the Strategy and Business Development
• Ms. Ben XiaoSenior Finance Director
• Mr. Yifan ChenJoint Company Secretary, Senior Director of the Legal Division
• Mr. Wing Yat LuiJoint Company Secretary
• Mr. Weidong LiuNon-Executive Director
• Dr. Xuelin GuIndependent Non-Executive Director
• Ms. Hui SunIndependent Non-Executive Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.